Niagen Bioscience Q3 net sales fell to $27.2 million; net loss of $1.2 million
Niagen Bioscience reported third-quarter 2026 results with net sales of $27.2 million, down from $34.0 million a year earlier, and a net loss of $1.2 million, compared with net income of $4.6 million in the prior-year quarter. The company said 2026 is an investment year, expects operating expenses to rise, and expects its ingredient business to be lower than last year, which weighs on shareholders' near-term earnings outlook.
Key points
- Q3 2026 net sales were $27.2 million, including $23.3 million from Tru Niagen, versus $34.0 million in Q3 2025.
- Net loss was $1.2 million, or $(0.01) per share, versus net income of $4.6 million in Q3 2025.
- Adjusted EBITDA, a non-GAAP measure, was $0.5 million, versus $6.4 million a year earlier.
- Cash and cash equivalents were $69.5 million at September 30, 2026, up from $66.7 million at June 30, 2026.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.